Approval · Notice of Compliance 31383 · 2023
OZEMPIC: Notice of Compliance 31383
Issued August 4, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31383
- Date
- August 4, 2023
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New concentration of the active ingredient
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OZEMPIC | 02540258 | Marketed |
Medicinal ingredients
- SEMAGLUTIDE 0.68 MG per ML